Factor XI Inhibition: Understanding Trial Data-Factor XI Inhibition: Understanding Trial Data

Video Transcription

Video Summary

Dr. Geoffrey Barnes reviews factor XI inhibitors and their promise as anticoagulants that may reduce thrombosis with less bleeding than current therapies. He explains the difference between hemostasis and pathologic thrombosis, and why factor XI inhibition may “decouple” clot prevention from bleeding risk. The talk covers drug types (antisense oligonucleotides, monoclonal antibodies, and small molecules), their onset and duration, and key phase II and III trial data in atrial fibrillation, stroke, acute coronary syndrome, and venous thromboembolism. He highlights encouraging bleeding reductions in phase II studies, especially with abelacimab, but notes mixed efficacy results for asundexian in atrial fibrillation. In contrast, asundexian showed benefit in secondary stroke prevention with very low bleeding. The lecture concludes that the best drug, dose, and clinical use cases remain uncertain, and ongoing phase III trials will determine whether factor XI inhibitors can replace or complement current anticoagulants.

Keywords

factor XI inhibitors

anticoagulants

bleeding risk

thrombosis

phase II and III trials

atrial fibrillation